ABT 925

Drug Profile

ABT 925

Alternative Names: A-437203; ABT-925; BSF-201640; DTA 201; LU 201640

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Antipsychotics; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 09 Nov 2007 Phase II trials are ongoing
  • 28 Mar 2001 Phase-II clinical trials for Schizophrenia (Unknown route)
  • 12 Nov 1999 Phase-I clinical trials for Schizophrenia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top